Cerenome, Inc. (CNSY)
0.7705
-0.03
(-3.81%)
USD |
NASDAQ |
Nov 12, 16:00
0.849
+0.08
(+10.19%)
After-Hours: 05:32
Cerenome Free Cash Flow (Quarterly) : -7.631M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.631M |
| March 31, 2026 | -7.056M |
| December 31, 2025 | -6.28M |
| September 30, 2025 | -2.582M |
| June 30, 2025 | -5.805M |
| March 31, 2025 | -6.175M |
| December 31, 2024 | -1.222M |
| September 30, 2024 | -3.694M |
| June 30, 2024 | -1.776M |
| March 31, 2024 | -4.553M |
| December 31, 2023 | -1.923M |
| September 30, 2023 | -2.409M |
| June 30, 2023 | -2.789M |
| March 31, 2023 | -5.89M |
| December 31, 2022 | -2.245M |
| September 30, 2022 | -4.255M |
| June 30, 2022 | -2.778M |
| March 31, 2022 | -4.203M |
| December 31, 2021 | -2.634M |
| September 30, 2021 | -2.305M |
| June 30, 2021 | -2.395M |
| March 31, 2021 | -3.09M |
| December 31, 2020 | -3.28M |
| September 30, 2020 | -1.913M |
| June 30, 2020 | -1.821M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.513M |
| December 31, 2019 | 0.977M |
| September 30, 2019 | -2.12M |
| June 30, 2019 | -1.554M |
| March 31, 2019 | -3.276M |
| December 31, 2018 | -2.493M |
| September 30, 2018 | -2.697M |
| June 30, 2018 | -2.746M |
| March 31, 2018 | -4.172M |
| December 31, 2017 | -4.248M |
| September 30, 2017 | -4.225M |
| June 30, 2017 | -5.161M |
| March 31, 2017 | -5.99M |
| December 31, 2016 | -4.118M |
| September 30, 2016 | -4.642M |
| June 30, 2016 | -5.713M |
| March 31, 2016 | -5.127M |
| December 31, 2015 | -4.589M |
| September 30, 2015 | -6.205M |
| June 30, 2015 | -5.081M |
| March 31, 2015 | -5.217M |
| December 31, 2014 | -4.928M |
| September 30, 2014 | -7.562M |
| June 30, 2014 | -9.455M |
| March 31, 2014 | -9.404M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 271.15M |
| Ernexa Therapeutics, Inc. | -3.17M |
| ACADIA Pharmaceuticals, Inc. | 10.26M |
| Anika Therapeutics, Inc. | 6.716M |
| Savara, Inc. | -42.82M |